Novo Nordisk Inc. (United States)

Novo Nordisk is a Danish pharmaceutical company and global leader in diabetes care, obesity treatment, and rare blood disorders. Key products include Ozempic and Wegovy (semaglutide) for type 2 diabetes and weight loss, Saxenda (liraglutide) for obesity, Tresiba and Levemir insulins, and NovoSeven for hemophilia. Novo Nordisk’s GLP-1 receptor agonists have transformed diabetes management and are revolutionizing obesity treatment worldwide.